Diabetes & Endocrinology Clinical Trials Update: Week 19, 2026

Published May 8, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

This Phase 3 study explores two doses of a medication called CagriSema alongside one dose of semaglutide to help people who are living with obesity, whether or not they also have type 2 diabetes. The goal is to find new ways to support weight loss which may improve overall health and reduce complications related to obesity and diabetes. This long-term study is actively recruiting participants from many countries and will last about 83 weeks, offering hope for more treatment options in the future.

Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1)

This Phase 3 trial tested a daily oral tablet form of semaglutide in adults who are overweight or living with obesity. If successful, this could provide an easier, pill-based treatment alternative to injections, helping more people manage their weight effectively. The study included participants from multiple countries and ran for about 18 months, assessing the impact on weight loss and potential health improvements.

Young Adults With Early-onset Obesity Treated With Semaglutide

This Phase 4 study focuses on young adults in Denmark who developed obesity early in life. It combines semaglutide treatment with lifestyle changes like diet and exercise. For those who struggle to lose weight through lifestyle alone, this treatment could offer a valuable new approach to reduce obesity and its related health risks. The study enrolled 246 participants and will provide insights into managing obesity in younger populations.

Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes

This Phase 3 trial is testing semaglutide in women who have glucose intolerance after experiencing gestational diabetes during pregnancy. The goal is to see if this treatment can lower the risk of developing type 2 diabetes later on. Recruiting 252 participants in Belgium, the study targets early intervention after pregnancy to improve long-term health for mothers at risk.

The Effect of Continuous Glucose Monitoring in Surgical Patients With Diabetes

This Phase 4 study evaluated the use of continuous glucose monitoring devices that provide real-time alerts to patients with diabetes undergoing surgery. Better glucose control during and after surgery can reduce complications and support safer recovery. The study included 200 patients in Denmark and has finished collecting data, with results expected to inform how glucose monitoring can improve surgical outcomes.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.